Smoking as a risk factor for end-stage renal failure in men with primary renal disease  by Orth, Stephan R. et al.
Smoking as a risk factor for end-stage renal failure in men with
primary renal disease
STEPHAN R. ORTH, AXEL STO¨CKMANN, CHRISTIAN CONRADT, and EBERHARD RITZ, in collaboration with
M. FERRO, W. KREUSSER, G. PICCOLI, M. RAMBAUSEK, D. ROCCATELLO, K. SCHA¨FER, H.G. SIEBERTH,
C. WANNER, B. WATSCHINGER, and P. ZUCCHELLI
Department of Internal Medicine and Institute for Medical Biometry, Ruperto Carola University Heidelberg, Heidelberg, Germany;
Aachen, Berlin, Duisburg, Heilbronn, and Wu¨rzburg, Germany; Bologna and Torino, Italy; Vienna, Austria
Smoking as a risk factor for end-stage renal failure in men with
primary renal disease.
Background. It is not known whether smoking increases the risk
of end-stage renal failure (ESRF) in patients with primary renal
disease.
Methods. We performed a retrospective multicenter case-con-
trol study including 582 patients from nine centers in Germany,
Italy and Austria. The diseases investigated were IgA glomerulo-
nephritis (IgA-GN) as a model of inflammatory renal disease and
autosomal dominant polycystic kidney disease (ADPKD) as a
model of non-inflammatory renal disease. Cases were patients
who had progressed to ESRF and controls were patients who were
not in ESRF, that is, whose serum-creatinine failed to progress to
.3 mg/dl during the observation period and who did not require
renal replacement therapy. Matching for renal disease (IgA-GN,
ADPKD), gender, age at renal death and region of residence
resulted in 102 individually matched pairs (IgA-GN N 5 54,
ADPKD N 5 48). Multiple conditional logistic regression was
used to estimate adjusted odds ratios for independent tobacco
effects.
Results. In men (matched pairs: IgA-GN N 5 44, ADPKD N 5
28), a significant dose-dependent increase of the risk to progress
to ESRF was found (non-adjusted). The baseline risk was defined
as ,5 pack-years (PY): (i) 5 to 15 PY, odds ratio 3.5 (95% CI 1.3
to 9.6), P 5 0.017; (ii) .15 PY 5 5.8 (2.0 to 17), P 5 0.001.
Systolic blood pressure, ACE inhibitor treatment and age at
diagnosis emerged as potential confounders. After adjustment,
the risk for ESRF in men with .5 PY was highly increased for
patients without ACE inhibitor treatment [10.1 (2.3 to 45), P 5
0.002] but not with ACE inhibitor treatment [1.4 (0.3 to 7.1), P 5
0.65].
Conclusion. Smoking increases the risk of ESRF in men with
inflammatory and non-inflammatory renal disease.
The health problems and costs associated with smoking
have recently been extensively reviewed [1–3]. The basic
problem is the addictive property of nicotine in tobacco
smoke, which explains the almost complete lack of change
in the prevalence of smoking in recent years in Europe and
the U.S.A. despite increasing awareness of its adverse
effects [3–5]. In fact, the prevalence in adolescents is
actually increasing.
In diabetic patients smoking has been repeatedly con-
firmed as an independent risk factor for onset and progres-
sion of diabetic nephropathy [6]. In insulin dependent and
independent diabetes mellitus the risk to develop mi-
croalbuminuria or proteinuria is substantially higher in
smokers, and smoking also accelerates the rate of progres-
sion of diabetic nephropathy to end-stage renal failure
(ESRF) [6, 7].
To date there is no information about the effects of
smoking on the course of non-diabetic renal disease.
Among others, the high cost of renal replacement therapy
is a strong incentive to identify factors that increase the risk
of renal failure and conversely to identify interventions that
may reduce progressive loss of renal function.
METHODS
A retrospective multicenter matched case-control study
was conducted to assess whether tobacco consumption
increases the risk to be in ESRF for patients with IgA
glomerulonephritis (IgA-GN) and autosomal-dominant
polycystic kidney disease (ADPKD). The study was ap-
proved by the Human Ethics Committee of the University
of Heidelberg, Germany.
Source and eligibility of study subjects
A pool of 582 patient records (N 5 180 patients with
ESRF, N 5 402 patients without ESRF) was obtained from
nine medical centers in Europe: Aachen, Berlin, Duisburg,
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Heidelberg, Heilbronn, and Wu¨rzburg in Germany; Bolo-
gna and Torino in Italy; Vienna in Austria. Inclusion
criteria were biopsy-proven IgA-GN or ultrasonography-
proven ADPKD, respectively. Exclusion criteria were sys-
temic diseases involving the kidney (such as, diabetes
mellitus, lupus erythematosus), immunosuppressive ther-
apy, and age at renal death less than 21 years.
Identification of case patients
Case patients were defined by the presence of ESRF,
that is, need of chronic hemodialysis therapy or kidney
transplantation.
Selection of controls
Controls were defined by the failure to progress to serum
creatinine values .3 mg/dl during a minimum observation
period of one year in the respective renal outpatient clinics
(minimum of three creatinine measurements during the
last year of observation). None of the controls required
renal replacement therapy.
Matching criteria
Patients were individually matched according to the
following criteria: renal disease (IgA-GN, ADPKD), gen-
der, region of residence, and age at renal death of cases (in
order to avoid misclassification of the controls they were
selected to be systematically older, that is, by 1 to 3 years,
than the corresponding cases).
Following these criteria, 102 pairs (male pairs, N 5 72;
female pairs, N 5 30) were obtained. IgA-GN was present
in 54 pairs (44 male, 10 female), whereas ADPKD was
present in 48 pairs (28 male, 20 female).
Assessment of smoking habits
The smoking habits of each patient were assessed using a
standardized questionnaire. Contact was made by mail,
asking the patients whether they agreed to participate in a
study on prognostic factors of renal diseases. The question-
naire was included in the letter to standardize the assess-
ment of smoking habits and to avoid interviewer bias.
Patients were not informed about the design of the study,
so that they did not know their status in the case-control
study. This procedure was chosen to avoid recall bias for
self reported data, that is, smoking history. Seventy-two
(17.9%) of the control patients and 22 (12.2%) of the cases
failed to return a completed questionnaire. Detailed infor-
mation about the type of tobacco consumption (cigarettes,
cigars, pipes) and the amount of tobacco consumed were
collected. The questionnaire allowed an assessment of
changes of smoking habits with time to permit accurate
calculation of the pack-years (PY) (see below). Further-
more, detailed information about alcohol consumption was
gathered as a “dummy” variable and internal consistency
control to evaluate whether the responses given were
plausible by comparison with the known proportions of
smokers and consumers of alcohol in the German popula-
tion.
Assessment of adjustment variables
Data on the use of medications or clinical parameters
with proven or potential effects on the evolution of renal
disease were obtained to adjust for possible differences
between cases and controls: age at diagnosis, blood pres-
sure and serum cholesterol at diagnosis, antihypertensive
treatment (specifically a history of treatment with ACE
inhibitors and calcium channel blockers), and treatment
with lipid-lowering agents during the time after the diag-
nosis had been made.
Statistical analysis
The individually matched pairs (N 5 102) were sub-
jected to statistical analysis. The amount of tobacco
consumed over time was defined as pack-years. The
potential duration of exposure to tobacco smoke was
made comparable for cases and controls by truncating
exposure history for each control at the age of renal
death of its matched case. The mean number of daily
cigarettes smoked was divided by 20 and multiplied by
the number of smoking years before age at renal death.
In a first step regression analysis was carried out to
estimate crude odds ratios by the use of conditional
logistic regression. The analysis was performed accord-
ing to the matching criteria. Analysis revealed strata
inhomogenity with respect to gender, which lead to
separate analysis of men and women. Multiple con-
ditional regression for matched pairs was used to esti-
mate the adjusted odds ratios for independent tobacco
effects.
RESULTS
The only form of tobacco consumption in the 204
patients encountered in the matched case-control study
was cigarette smoking. Table 1 shows selected character-
istics of the study population according to gender. For
both genders case and control patients were comparable
with respect to the following variables: serum choles-
terol, treatment with low protein diet, and treatment
with lipid-lowering agents. Furthermore, in male pa-
tients cases and controls were comparable with respect
to diastolic blood pressure, but differed with respect to
age at diagnosis, systolic blood pressure and antihyper-
tensive treatment. Differences in age at renal death of
cases and the corresponding age of controls are due to
the matching criteria (see above). At the time of last
analysis in controls the mean serum creatinine was 1.4 6
0.5 mg/dl in patients with IgA-GN and 1.8 6 0.6 mg/dl in
patients with ADPKD, respectively.
Analysis of tobacco consumption (given as PY) showed
no strata inhomogenity concerning renal disease, that is,
there was no interaction between smoking and underlying
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renal disease (P 5 0.56). Indeed, separate analysis for
IgA-GN and ADPKD had shown a similar risk ratio for ,5
PY and .5 PY: (i) for IgA-GN odds ratio 5.3 (P 5 0.006);
(ii) for ADPKD odds ratio 3.3 (P 5 0.07). Consequently,
IgA-GN and ADPKD were pooled for further analysis
In contrast, strata inhomogenity was found according to
gender (Table 2). Because of the small overall sample size
of female patients and the low proportion of female
smokers (33% vs. 51% in males) the subgroup of women
was excluded from further analysis. In the small subgroup
of women available for analysis, an effect of smoking on the
risk to be in ESRF could not be demonstrated: odds ratio
(95% CI) for .5 pack-years (PY) was 1.0 (0.3 to 3.4). In
contrast, in males smoking .5 PY the risk to be in ESRF
was increased with an odds ratio of 4.5 (1.9 to 10.9), P ,
0.001.
Table 3 shows the distribution of cigarette smoking in
male patients; consumption of cigarettes was subdivided
into three categories: 0 to 5, 5 to 15 and .15 PY. In the 73
individuals with 0 to 5 PY, only three individuals actually
smoked so that this category contained almost exclusively
nonsmokers. Strong smokers (.15 PY) were overrepre-
sented among the cases. Crude estimators for different
quantitative levels of smoking are given in Table 3. A more
sophisticated analysis to examine whether the effect of
smoking was monotonous or non-monotonous over the
range of PY under study was impossible in view of the
limited sample size.
Subsequent multiple logistic regression, including
ACE inhibitor treatment and systolic blood pressure,
revealed significant interaction between the smoking
variable and the indicator variable for ACE inhibitor
treatment (P 5 0.026). Therefore, analysis was stratified
for ACE inhibitor treatment and adjusted for systolic
blood pressure to take into consideration the imbalance
of this possible confounder. Estimators of the smoking-
related odds ratios according to ACE inhibitor treatment
were obtained (Table 4). The risk to be in ESRF was
substantially higher in smokers with no history of ACE
inhibitor treatment (odds ratio 10.1, 95% CI 2.3 to 45,
P 5 0.002). In contrast, the odds ratio for smokers with
a history of ACE inhibitor treatment was not significantly
increased (odds ratio 1.4, 95% CI 0.3 to 7.1, P 5 0.65;
Table 4).
Table 1. Selected characteristics of the study population
Age at
renal death
of cases
Age at
diagnosis
of renal
disease
Systolic
BP
Diastolic
BP
Antihypertensive
medication
ACE
inhibitors
Calcium
channel
blockers Serum-
cholesterol
mg/dl
Low-prot.
diet
Lipid-
lowering
drugs
years mm Hg N % N %
Men
Cases
(N 5 72)
47 6 11 39 6 12 146 6 21 91 6 11 45 (62) 18 (25) 23 (32) 222 6 55 14 (19) 9 (12)
Controls
(N 5 72)
49 6 11a 42 6 12 139 6 15 89 6 9 55 (76) 30 (42) 22 (31) 232 6 59 19 (26) 6 (8)
P-value 0.24 0.06 0.02 0.24 0.07 0.03 0.86 0.25 0.32 0.41
Women
Cases
(N 5 30)
48 6 8 37 6 10 138 6 23 90 6 13 22 (73) 6 (20) 10 (33) 228 6 58 3 (10) 6 (20)
Controls
(N 5 30)
51 6 9a 41 6 11 136 6 16 84 6 8 16 (53) 7 (23) 3 (10) 219 6 41 4 (13) 2 (7)
P-value 0.26 0.13 0.60 0.04 0.11 0.75 0.03 0.44 0.69 0.13
Abbreviations are: BP, blood pressure; ACE, angiotensin converting enzyme; prot., protein. Average of a minimum of three measurements at time
of different examinations, in dialyzed patients predialysis values.
a Age of controls, that is, patients without signs of end-stage renal failure (see Methods)
Table 2. Tobacco consumption (pack-years) in the study population
according to gender
Gender Cases Controls P value
Men (N 5 72/72) 16.9 6 20.2 8.2 6 14.9 0.001
IgA-GN (N 5 44/44) 16.9 6 20.7 8.8 6 16.5
ADPKD (N 5 28/28) 16.9 6 19.7 7.3 6 12.2
Women (N 5 60) 8.3 6 15.7 6.1 6 10.7 0.85
IgA-GN (N 5 10/10) 5.7 6 9.8 4.4 6 8.0
ADPKD (N 5 20/20) 9.5 6 18.0 7.0 6 12.0
Abbreviations are: IgA-GN, IgA glomerulonephritis; ADPKD, autoso-
mal dominant polycystic kidney disease.
Plus-minus values are means 6 SD.
a Two-sample Wilcoxon rank-sum test
Table 3. Crude tobacco-associated risk of end-stage renal failure in
male patients
Pack-years
Cases Controls
Odds ratio
95% Confidence
interval
P
valueaN %
0–5 26 (36) 47 (65) 1.0 — —
5–15 17 (24) 11 (15) 3.5 1.3–9.6 0.017
.15 29 (40) 14 (19) 5.8 2.0–17 0.001
a Wald x2 test
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Including age at diagnosis in the multivariate analysis did
not influence the estimators for the smoking-related odds
ratio (odds ratio 10.3, 95% CI 2.2 to 49).
DISCUSSION
The salient feature of the present retrospective multi-
center case-control study is the demonstration that in men
with inflammatory or non-inflammatory renal disease cig-
arette smoking significantly and dose-dependently in-
creases the odds ratios to be in ESRF. In view of the
relatively small number of matched pairs, low frequency of
smoking in this age group of women, as well as their lower
renal risk [8], female patients were excluded from multi-
variate statistical analysis; our failure to find an adverse
effect of smoking on renal prognosis in the small subgroup
of women available for analysis does certainly not exclude
an adverse effect of smoking, however.
The results of the study must be interpreted with caution.
Several potential confounding factors influence progression
of renal failure, that is, blood pressure, antihypertensive
treatment (particularly ACE inhibitors and calcium chan-
nel blockers), and diet. Not surprisingly, two factors were
found to be related to the risk to be in ESRF, that is, a
history of no ACE inhibitor treatment [9] and a history of
high systemic blood pressure [10] prior to the beginning of
renal replacement therapy. The latter may merely reflect
the known tendency for blood pressure to increase in
preterminal renal failure, although other explanations are
possible [11]. An interesting interaction between ACE
inhibitor treatment and risk of ESRF was noted: in indi-
viduals without a history of ACE inhibitor treatment smok-
ing strongly increased the risk to be in ESRF, whereas in
individuals with a history of ACE inhibitor treatment
smoking confered a much lower, and statistically not sig-
nificant, elevation of risk. Since the adverse effects of
smoking on progression of renal disease have been related
to intermittent blood pressure elevation and changes of
intrarenal hemodynamics [6], a beneficial effect of ACE
inhibitors, as suggested by the above data, would be
plausible. Because there is insufficient information on the
hemodynamic effects of smoking [12], and how it is affected
by ACE inhibitors, further speculation is certainly not
warranted.
Socioeconomic status was not assessed because of major
cultural differences across the countries included for this
study. It is sensible to assume that one major effect of
socioeconomic status relates to the accessibility to medical
care. We emphasize that as a result of largely socialized
medicine, accessibility to medical care was not an issue in
the three European countries where the study was con-
ducted. A number of items that may potentially be related
to socioeconomic status were considered in the analysis
(see “Assessment of adjustment variables” in the Methods
section).
The power of our study was not sufficient to go beyond
the statement that the effect was dose-dependent. Further
analysis providing information on a monotonous versus
non-monotonous relationship could not be provided. We
considered the potential artifact that smokers have a higher
risk of cardiovascular death [1, 2]. This is also true for
smokers with renal failure [13]. It is unlikely, however, that
selective survival of patients destined to develop ESRF
explains the above data.
This type of analysis does not strictly permit a differen-
tiation of whether onset of overt renal disease occured at an
earlier age or whether the rate of progression was acceler-
ated in smokers. For what it is worth, the known duration
of renal disease (Table 1) was similar in cases (on average
8 years) and controls (on average 7 years), but of course we
cannot exclude that, at least in IgA-GN, the renal disease
may have existed for a considerable time before renal
biopsy had been performed.
As far as the quality of data on smoking is concerned, we
emphasize that the questionnaire response rate was quite
satisfactory, that is, 82.1% of the 402 patients with no signs
of ESRF and 87.8% of the 180 patients with ESRF. Recall
bias for self reported data (that is, smoking history) was
avoided, because patients did not know their status in the
case-control study.
Furthermore, in German patients the proportion of
subjects reporting tobacco consumption (and alcohol con-
sumption, which was asked for as an internal consistency
control; data not given) was in good agreement with the
proportion reported for the general population by the
Federal Department of Statistics [5].
We admit that the retrospective case-control approach
has potential pitfalls. Prospective studies, preferably with
measurements of true glomerular filtration rate (GFR), are
therefore necessary to confirm the above results.
Our data are in agreement with several observations that
have been reported in the literature. According to a
preliminary report of the Multiple Risk Factor Intervention
Trial (MRFIT), an independent increase of the risk for
ESRF was found in smokers as compared to non-smokers
(up to 1.69 for heavy smokers) [14]. In ADPKD Chapman
et al. found that patients with established proteinuria as an
Table 4. Tobacco-associated risk (stratified for ACE inhibitor
treatment and adjusted for systolic blood pressure)
Pack-years
ACE inhibitor No ACE inhibitor
Odds
ratio
95%
Confidence
interval P valuea
Odds
ratio
95%
Confidence
interval P valuea
,5 1.0 — — 1.0 — —
.5 1.4 0.3–7.1 0.65 10.1 2.3–45 0.002
Patients treated with an ACE inhibitor: N 5 30 control and N 5 18 case
patients. Patients treated without an ACE inhibitor: N 5 42 control and
N 5 54 case patients.
a Wald x2 test
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indicator of adverse renal prognosis had not only higher
mean systemic blood pressure and more severe cystic
transformation of the kidney, but also a greater pack-year
smoking history than did their non-proteinuric counter-
parts [15]. In lupus nephritis, a retrospective cohort study
of 160 adults (median follow-up 6.4 years) documented that
smoking at the time of onset of nephritis was an indepen-
dent risk factor for faster development of ESRF [16]. The
median time interval to ESRF was 145 months in smokers
and more than 273 months in non-smokers. The best
documented and most extensive evidence for a deleterious
effect of smoking on the kidney concerns diabetic nephrop-
athy in patients with either insulin-dependent or non-
insulin-dependent diabetes [6, 7].
A deleterious effect of smoking on progression of renal
failure would be biologically plausible, since smoking may
theoretically cause renal injury through several of the
documented hemodynamic actions of nicotine [12], but we
acknowledge that non-hemodynamic actions of nicotine are
by no means excluded, as discussed elsewhere [reviewed in
6], such as, damage to endothelial cells, interference with
the coagulation/fibrinolysis systems, generation of oxygen
radicals, etc. Furthermore, a deleterious effect of com-
pounds other than nicotine in tobacco smoke is by no
means excluded.
Smokers are not more frequently hypertensive than
non-smokers [17], but since the first decade of this century
it has been known that smoking causes a transient increase
of blood pressure and heart rate [18]. These hemodynamic
actions are mediated, at least in part, via sympathetic
activation and vasopressin release [reviewed in 6]. In
addition, in patients with primary hypertension an increase
in cortisol, adrenocorticotrophic hormone (ACTH) and
plasma aldosterone concentration has been noted during
smoking [19]. Some studies using ambulatory blood pres-
sure measurements documented that smoking causes per-
sistent low grade elevation of blood pressure during the
daytime [20, 21]. Furthermore, some studies [22, 23] re-
ported that the night/day ratio of systolic and diastolic
blood pressure in healthy smokers was lower than in
non-smokers, indicating an altered diurnal rhythm of blood
pressure. Since a deleterious effect of even minor degrees
of elevated blood pressure on progression is well docu-
mented [10, 24], the intermittent and possibly persistent
increase in blood pressure induced by smoking may well
contribute to progression of diabetic and non-diabetic renal
disease.
We wish to draw attention to the potential public health
implications of our observation. For instance, in the Fed-
eral Republic of Germany more than 40,000 patients are
currently on dialysis. The annual treatment cost is approx-
imately DM 80,000 per patient, causing a total annual
expenditure of at least DM 3.2 billion (5 $1.8 billion U.S.).
According to our study 64% of the male dialysis patients
have a history of smoking. Since the risk to be in ESRF is
definitely increased in smokers, the potential financial
impact of the renal effects of smoking on the health budget
must be substantial.
In this context the question arises whether cessation of
smoking reverses the renal risk. At least one study in
patients with insulin-dependent diabetes mellitus and ne-
phropathy provided convincing evidence in this respect
[25]. In patients with adequate control of blood pressure
and glycemia the progression was considerably less when
patients stopped smoking. In another study, progression
was found in 53% of current smokers, 33% of ex-smokers
and 11% of non-smoker [26]. The implications for the
management of patients with diabetic or non-diabetic renal
disease are obvious.
Reprint requests to Dr. Stephan R. Orth, Department of Internal Medicine,
Section Nephrology, Medizinische Universita¨tsklinik Heidelberg, Bergheimer
Strasse 56a, D-69115 Heidelberg, Germany.
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